TriSalus Life Sciences (TLSI) News Today

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is receiving a potentially positive catalyst from new analyst coverage, although the company remains unprofitable in the near term.

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and an $11.00 price target, implying approximately 135.5% upside from the referenced $4.67 share price. The recommendation provides new analyst visibility and supports the bullish case for TLSI. HC Wainwright initiates coverage of TriSalus Life Sciences with a Buy rating
• Positive Sentiment: HC Wainwright’s forecasts point to improving long-term profitability. The firm estimates EPS of $0.09 in fiscal 2028, $0.57 in 2029 and $1.02 in 2030, suggesting expectations for substantial earnings growth as TriSalus expands its business.
• Neutral Sentiment: The analyst still expects losses through fiscal 2027, including EPS of negative $0.31 for 2026 and negative $0.28 for 2027. Quarterly loss estimates improve from negative $0.12 in the third quarter of 2026 to negative $0.02 in the fourth quarter of 2027, indicating gradual progress but continued reliance on execution and financing before profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 10, unchanged from the prior period. This indicates no measurable short-squeeze setup, but also no significant disclosed bearish short positioning.

Overall, TLSI’s recent weakness appears contrasted by a bullish new analyst target and a long-term profitability outlook. Near-term losses, the company’s high debt-to-equity ratio, and the absence of current earnings remain important risks for investors.